SCHEMBL3498783

SCHEMBL3498783

CCC1(C)CC2(CCCN(C(=O)OC(C)(C)C)C2)C(=O)O1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
USP30 Q70CQ3 2/20 0.38
MMP2 P08253 1/20 0.35
MMP13 P45452 1/20 0.35
MMP14 P50281 1/20 0.35
ADAM17 P78536 1/20 0.35
HPGD P15428 1/20 0.34
NR1H2 P55055 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
PIK3R1 P27986 2/20 0.34
PIK3CA P42336 2/20 0.34
MAPT P10636 2/20 0.33
SCD5 Q86SK9 1/20 0.33
KDM4E B2RXH2 1/20 0.33
THRB P10828 1/20 0.33
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
GRIN2B Q13224 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3496683 0.91 USP2 (0.37) USP2SMN1; SMN2USP30MMP2MMP13
SCHEMBL3495968 0.87 USP2 (0.43) USP2SMN1; SMN2USP30MMP2MMP13
SCHEMBL5765311 0.77 USP2 (0.47) USP2SMN1; SMN2USP30MMP2MMP13
SCHEMBL3498977 0.76 USP30 (0.45) USP2SMN1; SMN2USP30MMP2MMP13
SCHEMBL26378530 0.75 USP30 (0.43) USP2SMN1; SMN2USP30MMP2MMP13
SCHEMBL3498551 0.75 USP30 (0.40) USP2SMN1; SMN2USP30MMP2MMP13
SCHEMBL3499124 0.75 USP30 (0.47) USP2SMN1; SMN2USP30MMP2MMP13
SCHEMBL3497223 0.74 ACACB (0.43) USP2SMN1; SMN2USP30MMP2MMP13
SCHEMBL31645803 0.74 USP30 (0.42) USP2SMN1; SMN2USP30MMP2MMP13
SCHEMBL3494298 0.73 ACACB (0.58) ACACBACACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160255-A1 SPIRO-CYCLIC COMPOUND ACACA, CPT1B, PC USP2 4310/4885SMN1; SMN2 1291/4885USP30 3125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.